GeneluxGNLX
Market Cap: $81.8M
About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Employees: 24
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
7% more funds holding
Funds holding: 67 [Q1] → 72 (+5) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2.13% less ownership
Funds ownership: 22.74% [Q1] → 20.61% (-2.13%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
64% less capital invested
Capital invested by funds: $39.2M [Q1] → $14M (-$25.2M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Roth MKM Benjamin Paluch 100% 1-year accuracy 3 / 3 met price target | 322%upside $10 | Buy Initiated | 27 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 30% 1-year accuracy 27 / 91 met price target | 1,250%upside $32 | Buy Reiterated | 15 Aug 2024 |